Ocera Therapeutics, Inc. (OCRX) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) from a hold rating to a buy rating in a report issued on Tuesday, August 8th. They currently have $1.25 price target on the biopharmaceutical company’s stock.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
OCRX has been the topic of a number of other research reports. Aegis restated a buy rating and issued a $3.00 price target on shares of Ocera Therapeutics in a research report on Monday, April 17th. HC Wainwright restated a buy rating and issued a $4.00 price target on shares of Ocera Therapeutics in a research report on Wednesday, May 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $3.85.
Ocera Therapeutics (OCRX) opened at 1.031 on Tuesday. Ocera Therapeutics has a 52-week low of $0.52 and a 52-week high of $3.15. The stock’s market capitalization is $27.33 million. The firm’s 50-day moving average is $1.14 and its 200 day moving average is $1.08.
Ocera Therapeutics (NASDAQ:OCRX) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative net margin of 4,416.26% and a negative return on equity of 175.02%. On average, equities analysts forecast that Ocera Therapeutics will post ($1.08) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Ocera Therapeutics, Inc. (OCRX) Upgraded by Zacks Investment Research to Buy” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/18/ocera-therapeutics-inc-ocrx-rating-increased-to-buy-at-zacks-investment-research-updated.html.
A number of hedge funds have recently made changes to their positions in the stock. Virtu KCG Holdings LLC raised its stake in shares of Ocera Therapeutics by 194.6% in the second quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 141,040 shares during the period. Hikari Power Ltd raised its stake in shares of Ocera Therapeutics by 50.6% in the second quarter. Hikari Power Ltd now owns 376,596 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 126,596 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Ocera Therapeutics during the first quarter worth approximately $2,817,000. Finally, Renaissance Technologies LLC raised its stake in shares of Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 33,300 shares during the period. Institutional investors and hedge funds own 20.86% of the company’s stock.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.